AIA Group Ltd decreased its position in Dr. Reddy's Laboratories Ltd (NYSE:RDY - Free Report) by 69.8% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 43,857 shares of the company's stock after selling 101,293 shares during the quarter. AIA Group Ltd's holdings in Dr. Reddy's Laboratories were worth $578,000 at the end of the most recent quarter.
A number of other institutional investors also recently bought and sold shares of RDY. Costello Asset Management INC bought a new position in Dr. Reddy's Laboratories in the first quarter valued at about $26,000. Legacy Advisors LLC bought a new position in Dr. Reddy's Laboratories in the first quarter valued at about $41,000. Tower Research Capital LLC TRC lifted its holdings in Dr. Reddy's Laboratories by 623.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,032 shares of the company's stock valued at $48,000 after acquiring an additional 2,613 shares during the period. Allworth Financial LP grew its holdings in Dr. Reddy's Laboratories by 28.4% during the first quarter. Allworth Financial LP now owns 3,504 shares of the company's stock valued at $49,000 after purchasing an additional 776 shares during the period. Finally, Cullen Frost Bankers Inc. bought a new stake in Dr. Reddy's Laboratories during the first quarter valued at about $62,000. Institutional investors own 3.85% of the company's stock.
Analyst Ratings Changes
Several analysts have issued reports on the company. Wall Street Zen raised Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. Hsbc Global Res raised Dr. Reddy's Laboratories from a "hold" rating to a "strong-buy" rating in a report on Thursday, June 5th. Finally, HSBC raised Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating and boosted their price target for the company from $14.44 to $16.90 in a report on Thursday, June 5th. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Dr. Reddy's Laboratories currently has an average rating of "Buy" and a consensus target price of $16.95.
Read Our Latest Stock Analysis on Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Stock Performance
NYSE:RDY opened at $13.91 on Wednesday. The stock has a 50-day simple moving average of $14.82 and a two-hundred day simple moving average of $14.00. Dr. Reddy's Laboratories Ltd has a 52-week low of $12.26 and a 52-week high of $16.85. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.36 and a current ratio of 1.89. The firm has a market capitalization of $11.61 billion, a PE ratio of 21.07, a P/E/G ratio of 5.53 and a beta of 0.29.
Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The company reported $0.20 earnings per share for the quarter, topping analysts' consensus estimates of $0.18 by $0.02. The firm had revenue of $988.82 million during the quarter, compared to analyst estimates of $88.27 billion. Dr. Reddy's Laboratories had a return on equity of 17.25% and a net margin of 16.99%. Analysts forecast that Dr. Reddy's Laboratories Ltd will post 0.8 EPS for the current year.
Dr. Reddy's Laboratories Profile
(
Free Report)
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Dr. Reddy's Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Reddy's Laboratories wasn't on the list.
While Dr. Reddy's Laboratories currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.